Table 7.
Relationships between clinicopathological variables of NSCLC patients and BAFFR rs7290134 genotypes.
| Clinicopathological characteristics | Patients | Genotypes | p-value | Genotypes | p-value | ||
|---|---|---|---|---|---|---|---|
| n (%) | AA | AG+GG | GG | AG+AA | |||
| Total | 229 (100) | ||||||
| Genotyped | 229 (100) | 147 (64.2) | 82 (35.8) | 9 (3.9) | 220 (96.1) | ||
| NA | 0 (0) | ||||||
| Age (years) Mean (range) | |||||||
| Genotyped | 229 (100) | 49 (21.4) | 35 (15.3) | 0.198 | 4 (1.7) | 80 (34.9) | 0.728 |
| <65 | 84 (36.7) | 98 (42.8) | 47 (20.5) | 5 (2.2) | 140 (61.1) | ||
| >=65 | 145 (63.3) | ||||||
| Gender | |||||||
| Genotyped | 229 (100) | 133 (38.1) | 75 (32.8) | 1.000 | 6 (2.6) | 202 (88.2) | 0.039 |
| Male | 208 (90.8) | 14 (6.1) | 7 (3.1) | 3 (1.3) | 18 (7.9) | ||
| Female | 21 (9.2) | ||||||
| Smoking (pack-years) | |||||||
| Genotyped | 229 (100) | 57 (24.9) | 33 (14.4) | 0.923 | 6 (2.6) | 84 (36.7) | 0.752 |
| Cases | 90 (39.3) | 86.70 (10–180) | 87.85 (25–200) | 85.00 (30–153) | 87.27 (10–200) | ||
| Mean (range) | 87.12 (10–200) | 90 (39.3) | 49 (21.4) | 3 (1.3) | 136 (59.4) | ||
| NA | 139 (60.7) | ||||||
| Primary location | |||||||
| Genotyped | 229 (100) | 62 (27.1) | 38 (16.6) | 0.779 | 5 (2.2) | 95 (41.5) | 0.735 |
| Left lung | 100 (43.7) | 78 (34.1) | 43 (18.8) | 4 (1.7) | 117 (51.1) | ||
| Right lung | 121 (52.8) | 7 (3.1) | 1 (0.4) | 0 (0) | 8 (3.5) | ||
| NA | 8 (3.5) | ||||||
| Histology | |||||||
| Genotyped | 229 (100) | 72 (31.4) | 39 (17.0) | 0.353 | 4 (1.7) | 107 (46.7) | 0.772 |
| Squamous | 111 (48.5) | 61 (26.6) | 37 (16.2) | 4 (1.7) | 94 (41.0) | ||
| Adenocarcinoma | 98 (42.8) | 10 (4.4) | 2 (0.9) | 0 (0) | 12 (5.2) | ||
| Large carcinoma | 12 (5.2) | 4 (1.7) | 4 (1.7) | 1 (0.4) | 7 (3.1) | ||
| NA | 8 (3.5) | ||||||
| Stage | |||||||
| Genotyped | 229 (100) | 34 (14.8) | 24 (10.5) | 0.469 | 2 (0.9) | 56 (24.5) | 0.664 |
| I | 58 (25.3) | 30 (13.1) | 21 (9.2) | 2 (0.9) | 49 (21.4) | ||
| II | 51 (22.3) | 46 (20.1) | 23 (10.0) | 2 (0.9) | 67 (29.3) | ||
| III | 69 (30.1) | 28 (12.2) | 11 (4.8) | 3 (1.3) | 36 (15.7) | ||
| IV | 39 (17.0) | 9 (3.9) | 3 (1.3) | 3 (1.3) | 9 (3.9) | ||
| NA | 12 (5.2) | ||||||
| Grade | |||||||
| Genotyped | 229 (100) | 5 (2.2) | 1 (4.4) | 0.377 | 1 (0.4) | 5 (2.2) | 0.074 |
| I | 6 (2.6) | 50 (21.8) | 35 (15.3) | 4 (1.7) | 81 (35.4) | ||
| II | 85 (37.1) | 59 (25.8) | 31 (13.5) | 1 (4.4) | 89 (38.9) | ||
| III | 90 (39.3) | 33 (14.4) | 15 (6.6) | 3 (1.3) | 45 (19.7) | ||
| NA | 48 (21.0) | ||||||
| Maximum diameter (cm) | |||||||
| Genotyped | 229 (100) | 116 (50.1) | 71 (31.0) | 0.037 | 6 (2.6) | 181 (79.0) | 0.371 |
| Cases (%) | 187 (81.7) | 5.25 (0.7–21) | 4.24 (1.1–9.5) | 5.3 (3–7.5) | 4.85 (0.7–21) | ||
| Mean (range) | 4.87 (0.7–21) | 31 (13.5) | 11 (4.8) | 3 (1.3) | 39 (17.0) | ||
| NA | 42 (18.3) | ||||||
| Lymph node infiltration | |||||||
| Genotyped | 229 (100) | 56 (24.5) | 35 (15.2) | 0.874 | 4 (1.7) | 87 (38.0) | 0.373 |
| No | 91 (39.7) | 51 (22.3) | 29 (12.7) | 1 (0.4) | 79 (34.5) | ||
| Yes | 80 (34.9) | 40 (17.5) | 18 (7.9) | 4 (1.7) | 54 (23.6) | ||
| NA | 58 (25.3) | ||||||
| Metastasis (adrenals)a | |||||||
| Genotyped | 229 (100) | 26 (11.4) | 10 (4.4) | 0.301 | 1 (0.4) | 35 (15.3) | 1.000 |
| No | 36 (15.7) | 14 (6.1) | 2 (0.9) | 0 (0) | 16 (7.0) | ||
| Yes | 16 (7.0) | 107 (46.7) | 70 (30.6) | 8 (3.5) | 169 (73.8) | ||
| NA | 177 (77.3) | ||||||
| Metastasis (liver)a | |||||||
| Genotyped | 229 (100) | 1.000 | |||||
| No | 34 (14.8) | 24 (10.5) | 10 (4.4) | 0.329 | 1 (0.4) | 33 (14.4) | |
| Yes | 20 (8.7) | 17 (7.4) | 3 (1.3) | 1 (0.4) | 19 (8.3) | ||
| NA | 175 (76.4) | 106 (46.3) | 69 (30.1) | 7 (3.1) | 168 (73.4) | ||
| Metastasis (brain)a | |||||||
| Genotyped | 229 (100) | 25 (10.9) | 9 (3.9) | 0.791 | 0 (0) | 34 (14.8) | 0.114 |
| No | 34 (14.8) | 23 (10.0) | 11 (4.8) | 4 (1.7) | 30 (13.1) | ||
| Yes | 34 14.8) | 99 (43.2) | 62 (27.1) | 5 (2.2) | 156 (68.1) | ||
| NA | 161 (70.3) | ||||||
| Metastasis (bones)a | |||||||
| Genotyped | 229 (100) | 21 (9.2) | 9 (3.9) | 0.797 | 1 (0.4) | 29 (12.7) | 1.000 |
| No | 30 (13.1) | 25 (10.9) | 14 (6.1) | 2 (0.9) | 37 (16.2) | ||
| Yes | 39 (17.0) | 101 (44.1) | 59 (25.8) | 6 (2.6) | 154 (67.2) | ||
| NA | 160 (69.9) | ||||||
| Metastasis (adrenals–liver–brain–bones)a | |||||||
| Genotyped | 229 (100) | 9 (3.9) | 4 (1.7) | 1.000 | 0 (0) | 13 (5.7) | 1.000 |
| No | 13 (5.7) | 50 (21.8) | 24 (10.7) | 4 (1.7) | 70 (30.6) | ||
| Yes | 74 (32.3) | 88 (39.3) | 54 (23.6) | 5 (2.2) | 137 (59.8) | ||
| NA | 142 (62.0) | ||||||
| Survival (2 years) | |||||||
| Genotyped | 229 (100) | 74 (32.3) | 31 (13.5) | 0.092 | 4 (1.7) | 101 (44.1) | 1.000 |
| Dead | 105 (45.9) | 69 (30.1) | 48 (21.0) | 4 (1.7) | 113 (49.3) | ||
| Alive | 117 (51.1) | 4 (1.7) | 3 (1.3) | 1 (0.4) | 6 (2.6) | ||
| NA | 7 (3.1) | ||||||
| Survival (3 years) | |||||||
| Genotyped | 229 (100) | 91 (39.7) | 44 (19.2) | 0.249 | 6 (2.6) | 129 (56.3) | 0.714 |
| Dead | 135 (59.0) | 50 (21.8) | 34 (14.8) | 2 (0.9) | 82 (35.8) | ||
| Alive | 84 (36.7) | 6 (2.6) | 4 (1.7) | 1 (0.4) | 9 (3.9) | ||
| NA | 10 (4.4) | ||||||
| Survival (5 years) | |||||||
| Genotyped | 229 (100) | 107 (46.7) | 50 (21.8) | 0.084 | 6 (2.6) | 151 (66.0) | 1.000 |
| Dead | 157 (68.6) | 34 (14.8) | 28 (12.2) | 2 (0.9) | 60 (26.2) | ||
| Alive | 62 (27.1) | 6 (2.6) | 4 (1.7) | 1 (0.4) | 9 (3.9) | ||
| NA | 10 (4.4) | ||||||
NA, data not available or unknown.
a
Metastasis detected at follow-up, not at the time of sample collection.